###begin article-title 0
###xml 65 73 61 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Vitro</italic>
###xml 78 85 74 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Vivo</italic>
The Epoxygenases CYP2J2 Activates the Nuclear Receptor PPARalpha In Vitro and In Vivo
###end article-title 0
###begin p 1
Conceived and designed the experiments: MS DZ LMD JAB MH TW DBB. Performed the experiments: JW DZ GG SS LMD JAB DBB. Analyzed the data: JW MS GG SS MH TW DBB. Contributed reagents/materials/analysis tools: DZ DBB. Wrote the paper: JW MS MH DBB.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 634 639 <span type="species:ncbi:9606">human</span>
Peroxisome proliferator-activated receptors (PPARs) are a family of three (PPARalpha, -beta/delta, and -gamma) nuclear receptors. In particular, PPARalpha is involved in regulation of fatty acid metabolism, cell growth and inflammation. PPARalpha mediates the cardiac fasting response, increasing fatty acid metabolism, decreasing glucose utilisation, and is the target for the fibrate lipid-lowering class of drugs. However, little is known regarding the endogenous generation of PPAR ligands. CYP2J2 is a lipid metabolising cytochrome P450, which produces anti-inflammatory mediators, and is considered the major epoxygenase in the human heart.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 21 29 21 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 327 333 311 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n vivo</italic>
###xml 362 377 <span type="species:ncbi:10090">transgenic mice</span>
Expression of CYP2J2 in vitro results in an activation of PPAR responses with a particular preference for PPARalpha. The CYP2J2 products 8,9- and 11-12-EET also activate PPARalpha. In vitro, PPARalpha activation by its selective ligand induces the PPARalpha target gene pyruvate dehydrogenase kinase (PDK)4 in cardiac tissue. In vivo, in cardiac-specific CYP2J2 transgenic mice, fasting selectively augments the expression of PDK4.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 61 69 57 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 74 81 70 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Our results establish that CYP2J2 produces PPARalpha ligands in vitro and in vivo, and suggests that lipid metabolising CYPs are prime candidates for the integration of global lipid changes to transcriptional signalling events.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 368 371 368 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-BishopBailey1">[1]</xref>
###xml 373 376 373 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Marx1">[2]</xref>
###xml 747 750 747 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-BishopBailey1">[1]</xref>
###xml 767 770 767 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Delerive1">[3]</xref>
###xml 793 796 793 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Ziouzenkova1">[4]</xref>
###xml 1177 1180 1169 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Cowart1">[5]</xref>
###xml 1255 1258 1243 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Fang1">[6]</xref>
###xml 1273 1276 1257 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Liu1">[7]</xref>
###xml 1278 1281 1262 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Liu2">[8]</xref>
###xml 1281 1289 1265 1273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1429 1436 1413 1420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Exogenous PPAR activators include a number of fatty acids as well as a variety of eicosanoid, HETEs, HODEs, prostaglandins, and leukotrienes. A number of lipid-metabolising pathways have therefore been suggested as sources of PPAR ligands, however none really fully satisfy the criteria required for them to be regarded as ubiquitous endogenous PPAR ligand generators [1], [2]. The cyclooxygenase, and 5-, 12/15-lipoxygenase pathways are good examples: prostanoid synthase enzymes and lipoxygenase isoforms have a highly tissue-specific expression pattern that do not fully match those of the PPARs and the effects of prostanoid/lipoxygenase enzyme inhibitors or the phenotypes of the corresponding knockout animal do not match those of the PPARs [1]. Phospholipases [3] or lipoprotein lipase [4] can produce PPARalpha ligands from circulating lipoproteins. However, it is unclear whether these enzymes produce PPAR ligands universally. A very attractive hypothesis is that cytochrome P450 enzymes (CYPs) could provide the link. Similar to related eicosanoids, 8,9-, 11,12-, and 14,15-EET and their CYP4A hydroxylase metabolites can bind and activate a PPARalpha reporter gene [5], and 8,9-, 11,12- and 14,15-EETs can functionally activate both PPARalpha [6] and PPARgamma [7], [8]in vitro. It is not known however, which CYPs act as potential sources of the EETs, or whether CYPs or EETs mediate any functional effects on PPARs in vivo.
###end p 9
###begin p 10
###xml 253 256 245 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Zeldin1">[9]</xref>
###xml 506 509 498 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Zeldin1">[9]</xref>
###xml 511 515 503 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Spiecker1">[10]</xref>
###xml 649 653 641 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Spiecker1">[10]</xref>
###xml 695 703 683 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 708 715 696 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 377 380 <span type="species:ncbi:9606">man</span>
There are more than 500 CYP genes primarily associated with the metabolism and detoxification of foreign chemicals. A number of CYPs also catalyze the metabolism of lipids by epoxygenases lipoxygenase-like, and omega- and omega-1-hydroxylase activities [9]. The CYP2 gene family of epoxygenases has approximately 25 members. CYP2J2 is the only CYP2J family member expressed in man, and it is localised in the heart and vasculature, throughout the gastro-intestinal and respiratory tracts and in the kidney [9], [10], where it catalyses the conversion of arachidonic acid via the epoxygenase pathway to anti-inflammatory and vascular-protective EETs [10]. Here we show CYP2J2 activates PPARalpha in vitro and in vivo.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
###xml 23 31 23 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
CYP2J2 activates PPARs in vitro in an autocrine manner
###end title 12
###begin p 13
###xml 109 118 109 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g001">Figure 1A</xref>
###xml 163 172 159 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g001">Figure 1A</xref>
###xml 199 208 187 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g001">Figure 1B</xref>
###xml 348 357 332 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g001">Figure 1A</xref>
###xml 488 492 464 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-He1">[11]</xref>
###xml 760 769 732 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g001">Figure 1A</xref>
###xml 872 878 840 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">active</italic>
###xml 1027 1035 991 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g002">Figure 2</xref>
Transient transfection of the CYP2J2 cDNA in HEK293 cells produced significant expression of CYP2J2 protein (Figure 1A). The combination of CYP2J2 with PPARalpha (Figure 1A), PPARdelta or PPARgamma (Figure 1B) induced a synergistic activation of PPAR reporter genes, with a marked preference in terms of absolute activity for PPARalpha activation (Figure 1A). pDR-1 was used as a reporter gene for PPARdelta activation due to the reported lack of efficacy for pACO on PPARdelta responses [11]. A functional PPAR was required for this activation, as no significant reporter gene activation was seen in cells co-transfected with vector reporter gene lacking the PPRE (data not shown), or when cells were co-transfected with dominant-negative (DN)-PPARalpha [12; Figure 1A). Similarly, the activation of PPAR reporter gene by co-transfection of PPARalpha and CYP2J2 required active CYP2J2, as the epoxygenase inhibitor SKF525A caused a concentration-dependent inhibition of PPARalpha-CYP2J2 induced PPAR reporter gene activation (Figure 2). These endogenous products of CYP2J2 act in an intracellular manner, as only when cells are co-transfected so that PPARalpha and CYP2J2 are co-expressed together in the same cell is a significant synergistic activation of the PPAR reporter gene detected (data not shown).
###end p 13
###begin title 14
###xml 32 40 32 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
CYP2J2 activates PPAR responses in vitro. CYP2J2 synergises with PPARalpha (A), PPARbeta/delta or PPARgamma (B) to induce PPAR reporter gene activation.
###end title 14
###begin p 15
Dominant-negative (DN-)PPARalpha co-transfected into cells with CYP2J2 and PPARalpha abolished the ability of CYP2J2 to activate PPARalpha (A). HEK293 cells were transfected with PPAR reporter genes (pACO.gLuc for PPARalpha and -gamma, and pDR-1 for PPARdelta), and pcDNA-CYP2J2, pCMX-PPARalpha, pCMX-PPARdelta, or pCMX-PPARgamma alone, or co-transfected with CYP2J2 and the individual PPAR (2J2+alpha, 2J2+delta, and 2J2+gamma). All PPAR reporter gene activation studies are represented as fold luciferase from PPAR response element transfection alone (control), normalised to total protein at 20 h post-transfection. Total plasmid DNA for transfections was normalised using pcDNA3.1 throughout. Data represents n = 9-12 replications from 4 separate experiments. * denotes p<0.05 by one-sample t-test between control and transfected cells. Inset (A) is Western blot for CYP2J2 and RT-PCR for PPARalpha in cells with either mock transfected (-; pcDNA3.1) or cells transfected with pcDNA-CYP2J2 and pcDNA-mPPARalpha (+).
###end p 15
###begin title 16
Synergistic activation of PPARalpha by CYP2J2 requires an active CYP2J2.
###end title 16
###begin p 17
Cells were co-transfected with PPAR reporter gene, CYP2J2 and PPARalpha, and treated with the epoxygenase inhibitor SKF525A (0-30 microM). SKF525A caused a concentration-dependant inhibition of PPAR reporter gene activation. Data represents n = 9-12 replications from 4 separate experiments.
###end p 17
###begin title 18
CYP2J2 activates PPARalpha and inhibits NFkappaB activation
###end title 18
###begin p 19
###xml 112 115 104 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-BishopBailey1">[1]</xref>
###xml 117 120 109 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Marx1">[2]</xref>
###xml 365 373 343 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g003">Figure 3</xref>
###xml 516 524 479 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g003">Figure 3</xref>
PPARalpha activation inhibits the activation of the pro-inflammatory and survival transcription factor NFkappaB [1], [2]. IL-1beta (10 ng/ml) induced NFkappaB reporter gene activation in HEK293 cells transfected with control plasmid cDNA. In cells transfected with the combination of CYP2J2 and PPARalpha, IL-1beta induced NFkB activation was completely abolished (Figure 3). Inhibiting CYP2J2 with SKF525A (10 microM) restored the ability of IL-1beta to activate NFkappaB in PPARalpha and CYP2J2 transfected cells (Figure 3)
###end p 19
###begin title 20
CYP2J2 activates PPARalpha to inhibit NFkappaB activation.
###end title 20
###begin p 21
IL-1beta (10 ng/ml; 20 h) induced NFkappaB reporter gene activation in HEK293 cells. Cells co-transfected with CYP2J2 and PPARalpha abolished IL-1beta-induced NFkappaB activation. Co-incubation of cells with the epoxygenases inhibitor SKF525A (10 microM) had no effect on IL-1beta induced NFkappaB activation, but reversed the ability of PPARalpha and CYP2J2 to inhibit IL-1beta induced NFkappaB activation. HEK293 cells were transfected with NFkappaB reporter gene and pcDNA-CYP2J2 and pCMX-PPARalpha. Data is represented as fold luciferase from NFkappaB reporter transfection alone (control), normalised to total protein at 20 h post-transfection. Total plasmid DNA for transfections was normalised using pcDNA3.1 throughout. Data represents n = 6 replications from 3 separate experiments. * denotes p<0.05 by paired t-test between IL-1b and treatments.
###end p 21
###begin title 22
EETs activate PPARalpha
###end title 22
###begin p 23
###xml 142 150 138 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g004">Figure 4</xref>
###xml 230 238 226 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g004">Figure 4</xref>
###xml 294 303 290 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g005">Figure 5A</xref>
###xml 442 445 434 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Cowart1">[5]</xref>
###xml 524 533 512 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g005">Figure 5B</xref>
###xml 690 699 670 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g004">Figure 4B</xref>
8,9- and 11,12-EET at nM concentrations induced activation of PPAR in HEK293 cells in the presence, but not absence of transfected PPARalpha (Figure 4). The CYP products 14,15-EET, or 5,6-DiHETE, the stable metabolite of 5,6-EET (Figure 4) or the linoleic acid metabolite of CYP2J2 leukotoxin (Figure 5A) had no effect on PPARalpha reporter gene activation. Although, 14,15-EET had no effect in our hands, consistent with the previous report [5], the CYP4A hydroxylase 14,15-EET metabolite was a potent PPARalpha activator (Figure 5B). The activation of PPARalpha responses by 8,9-EET or 11,12-EET was completely reversed when cells were co-transfected with dominant negative DN-PPARalpha (Figure 4B).
###end p 23
###begin title 24
CYP products activate PPARalpha. (A) 8,9-EET, and 11,12-EET, but not 14,15-EET, or 5,6-DiHETE, induce PPAR reporter gene activation in cells transfected with PPARalpha (with out PPARalpha, closed squares; +PPARalpha closed circles).
###end title 24
###begin p 25
HEK293 cells were transfected with PPAR reporter gene in the presence or absence of PPARalpha. 20 h post transfection cells were treated with CYP2J2 products (0-10 microM), for a further 20 h. * denotes p<0.05 by one-way ANOVA followed by Bonferroni's post test. (B) 8,9-EET and 11,12-EET activation of PPARalpha responses were inhibited by co-transfection with dominant-negative DN-PPARalpha. Cells were transfected with a PPAR reporter alone or with PPARalpha, in the presence or absence of DN-PPARalpha. Cells were treated with CYP2J2 products as indicated (all at 1 microM). Data represents n = 9-12 replications from 3-4 separate experiments. * denotes p<0.05 by one-sample t-test between control and transfected cells.
###end p 25
###begin title 26
Alternative CYP products and PPARalpha activation.
###end title 26
###begin p 27
(A) PPAR reporter gene activation is not induced by the linoleic acid CYP2J2 metabolite leukotoxin in the presence or absence of PPARalpha, but is potently induced by (B) the CYP4A 14,15-EET metabolite 20,14,15-HEET in the presence of PPARalpha. HEK293 cells were transfected with PPAR reporter gene in the presence or absence of PPARalpha. 20 h post transfection cells were treated with CYP2J2 products (0-10 microM), for a further 20 h.
###end p 27
###begin title 28
###xml 52 60 48 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
PPARalpha activation induces PDK4 in cardiac tissue in vitro
###end title 28
###begin p 29
###xml 135 139 131 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Roberts1">[12]</xref>
###xml 141 145 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Sugden1">[13]</xref>
###xml 245 253 237 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 255 263 247 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g006">Figure 6</xref>
###xml 361 369 349 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g006">Figure 6</xref>
###xml 213 218 <span type="species:ncbi:10090">mouse</span>
###xml 418 422 <span type="species:ncbi:10090">mice</span>
PDK4 is a tissue specific PPARalpha target gene that facilitates fatty acid oxidation by "sparing" pyruvate for oxaloacetate formation [12], [13]. The highly selective PPARalpha ligand GW7647 induced PDK4 mRNA in mouse cardiac tissue in culture in vitro (Figure 6); an effect which was abolished by co-incubation with the selective PPARalpha antagonist GW6471 (Figure 6), or if tissue was used from PPARalpha knockout mice (data not shown).
###end p 29
###begin title 30
PPARalpha activation induces the PPARalpha target gene PDK4 in heart segments in organ culture.
###end title 30
###begin p 31
###xml 6 11 <span type="species:ncbi:10090">mouse</span>
Fresh mouse heart tissue in culture was incubated in the presence or absence of the selective PPARalpha agonist GW7647 (10 nM) or antagonist GW6471 (3 microM) for 24 h and PDK4, PPARalpha and beta-actin expression determined by RT-PCR. *denotes p<0.05 by one-sample t-test between control and treatments. Data represents mean+/-SEM of n = 9 incubations from 3 separate experiments.
###end p 31
###begin title 32
###xml 24 39 <span type="species:ncbi:10090">transgenic mice</span>
Cardiac-specific CYP2J2 transgenic mice have an elevated PPARalpha response during fasting
###end title 32
###begin p 33
###xml 56 63 52 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 315 319 303 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Wu1">[14]</xref>
###xml 379 386 363 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 310 314 <span type="species:ncbi:10090">mice</span>
The fasting response is a model of PPARalpha activation in vivo as a decline in insulin levels and/or a rise in lipid fuel availability facilitates PPARalpha activation and the up-regulation of PDK4. Moreover, this marked up-regulation of PDK4 expression in response to fasting is absent in PPARalpha knockout mice [14]. Therefore, PDK4 is a robust index of PPARalpha activation in vivo. Expression of the related proteins PDK1, PDK2 and E1a are not regulated by PPARalpha, and were used as controls.
###end p 33
###begin p 34
###xml 128 132 128 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Seubert1">[15]</xref>
###xml 276 284 276 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g006">Figure 6</xref>
###xml 390 405 390 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g007">Figure 7A and B</xref>
###xml 426 435 426 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g007">Figure 7C</xref>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
###xml 450 454 <span type="species:ncbi:10090">mice</span>
###xml 495 499 <span type="species:ncbi:10090">mice</span>
###xml 584 588 <span type="species:ncbi:10090">mice</span>
###xml 716 720 <span type="species:ncbi:10090">mice</span>
Cardiomyocyte-specific CYP2J2 transgenic (Tr) mice have been generated and have a normal heart anatomy and contractile function [15]. Fed CYP2J2 Tr mice had no altered expression of PDK1, -2, -4 or E1a expression in the heart, kidney, or liver compared to wild type controls (Figure 6; and data not shown). In fasted mice, PDK4 protein expression was selectively up-regulated in the heart (Figure 7A and B), kidney and liver (Figure 7C) of wild type mice. In response to fasting, wild type male mice had an approximate 2-3 fold higher induction of cardiac PDK4 expression than female mice (9.3+/-2.4 male compared to 3.7+/-0.9 female; relative fold induction; n = 4-6). The basal PDK4 levels between male and female mice were equivalent, so this gender difference in PPARalpha activity/PDK4 expression upon fasting is gender specific.
###end p 34
###begin title 35
###xml 26 33 22 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
CYP2J2 augments PPARalpha in vivo in the fasting model of PPARalpha activation.
###end title 35
###begin p 36
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 354 358 <span type="species:ncbi:10090">mice</span>
###xml 640 644 <span type="species:ncbi:10090">mice</span>
###xml 1008 1023 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1114 1129 <span type="species:ncbi:10090">transgenic mice</span>
Female wild-type or cardiac-specific CYP2J2 Tr mice were allowed food and water ad libitum, or fasted for 24 h. Figure (A) shows representative western blots for 2 of the 6 animals tested for PDK4, PDK1 (antibody has cross reactivity with PDK4 indicated by changes in the lower band) and E1a in the hearts of wild type (WT) or cardiac-specific CYP2J2 Tr mice (2J2); specific bands are identified by the arrows. Figures show the relative protein expression of PDK4 in the heart (B), kidney, and liver (C as indicated) and PDK1 and E1a in the heart (as indicated) in wild type (WT) and cardiac-specific CYP2J2 Tr (2J2), fed and fasted female mice. Data represents relative densitometry of protein compared to wild type fed controls for n = 4-6 separate animals in each group. Only the PPARalpha target gene PDK4 was induced on fasting both in the heart and kidney. Upon fasting there was an approximate doubling of PDK4 in the hearts (b), but not the kidney (e), or liver (f) of female cardiac specific CYP2J2 transgenic mice. * denotes p<0.05 by unpaired t-test between the fasting response in wild-type and CYP2J2 transgenic mice.
###end p 36
###begin p 37
###xml 303 311 299 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g007">Figure 7</xref>
###xml 408 416 404 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007421-g006">Figure 6</xref>
###xml 43 47 <span type="species:ncbi:10090">mice</span>
Upon fasting, male wild type and CYP2J2 Tr mice, had a comparable induction of cardiac PDK4 protein (9.3+/-2.4 wild type; 7.4+/-1.3 CYP2J2 Tr; fold expression; n = 4). In contrast, female CYP2J2 Tr exhibited a much greater induction of cardiac PDK4 protein upon fasting compared to wild- type controls (Figure 7). PDK1, PDK2 and E1a protein expression were unchanged by 24 h of fasting in any tissue tested (Figure 6, and data not shown).
###end p 37
###begin p 38
###xml 94 98 94 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Sugden1">[13]</xref>
###xml 100 104 100 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Wu1">[14]</xref>
###xml 106 110 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Barger1">[16]</xref>
###xml 230 237 230 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007421-t001">Table 1</xref>
###xml 329 332 329 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Marx1">[2]</xref>
###xml 455 462 455 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007421-t001">Table 1</xref>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
###xml 449 453 <span type="species:ncbi:10090">mice</span>
###xml 636 641 <span type="species:ncbi:10090">mouse</span>
Up-regulation of PDK4 expression is linked to a decline in circulating insulin concentrations [13], [14], [16]. Upon fasting, both plasma insulin and blood glucose levels fell to equivalent levels in wild type and CYP2J2 Tr mice (Table 1). Fibrate administration is associated with suppression of circulating triglyceride levels [2], however, neither triglyceride nor non-esterified fatty acid concentrations were affected in wild type or CYP2J2 Tr mice (Table 1). Since no systemic metabolic differences were observed, any changes in PPAR response we conclude are due to the local cardiac specific activity of CYP2J2 in the transgenic mouse.
###end p 38
###begin title 39
###xml 73 88 <span type="species:ncbi:10090">transgenic mice</span>
Blood parameters in fed and fasted wild type and cardiac-specific CYP2J2 transgenic mice (CYP2J2).
###end title 39
###begin p 40
###xml 21 25 <span type="species:ncbi:10090">mice</span>
###xml 236 240 <span type="species:ncbi:10090">mice</span>
Wild type and CYP2J2 mice have similar basal levels of plasma insulin, blood glucose, non-esterified fatty acids (NEFA) and triglycerides. Following 24 h of fasting, plasma insulin and blood glucose dropped in both wild type and CYP2J2 mice to equivalent levels, while non-esterified fatty acids and triglycerides remained relatively unchanged. This data represents the mean+/-s.e.m. for n = 6 animals per group. * denotes p<0.05 by unpaired t-test between fed and fasted levels.
###end p 40
###begin title 41
Endogenous CYPs and the cardiac fasting response
###end title 41
###begin p 42
###xml 42 49 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 239 243 239 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Athirakul1">[17]</xref>
###xml 459 467 459 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007421.s001">Table S1</xref>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
###xml 254 260 <span type="species:ncbi:10090">murine</span>
###xml 515 519 <span type="species:ncbi:10090">mice</span>
The use of pharmacological CYP inhibitors in vivo is complicated due both to lack of specificity of inhibitors and the great heterogeneity in CYP enzymes between species. We did however examine the fasting response in CYP2J5 knockout mice [17], the only murine CYP2J family member where a knockout has been generated. There was however no difference in the circulating blood glucose levels, or the heart, liver or kidney PDK4, or heart E1a expression levels (Table S1) between knockout and wild type male or female mice either under fed or fasted conditions.
###end p 42
###begin title 43
Discussion
###end title 43
###begin p 44
###xml 289 297 289 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 854 862 819 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 862 865 827 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Liu1">[7]</xref>
###xml 867 870 832 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Liu2">[8]</xref>
###xml 385 389 <span type="species:ncbi:10090">mice</span>
###xml 830 835 <span type="species:ncbi:9606">human</span>
The nature of endogenous PPAR ligands are still far from clear, as is whether PPARs act as general lipid sensors or whether high affinity ligands exist in the body. Here we show CYP2J2 can act as an endogenous epoxygenase source of high affinity PPAR ligands. When co-transfected together in vitro, CYP2J2 induces PPAR, in particular PPARalpha, activity. In cardiac-specific-CYP2J2 Tr mice, fasting greatly elevates the PPARalpha target gene PDK4. These results do not exclude a role for CYP2J2 or other CYPs as regulators of PPARbeta/delta or -gamma. Indeed we found CYP2J2 can activate PPARdelta and PPARgamma, (albeit it to lower absolute levels then PPARalpha in our transfection system) and it is known that lipid CYP products (though not the CYP responsible) are endogenous PPARgamma activators, induced by laminar shear of human endothelial cells in vitro[7], [8].
###end p 44
###begin p 45
###xml 79 83 79 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Huang1">[18]</xref>
###xml 288 295 288 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 420 423 420 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Delerive1">[3]</xref>
###xml 447 450 447 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Ziouzenkova1">[4]</xref>
Unlike other proposed PPAR ligand-generating enzymes (e.g. 12/15-lipoxygenase; [18]), CYP2J2 did not require additional arachidonic/linoleic acid substrate(s), suggesting a high level of functional coupling between the epoxygenases and PPARs. We also show for the first time a functional in vivo response for a PPAR ligand generating system. Our results do not rule out the role of other enzymes, such as phospholipases [3] or lipoprotein lipases [4] implicated in PPARalpha ligand generation. These enzymes are likely to produce PPAR ligands in parallel to CYPs, and/or supply free fatty acid substrates for CYPs to utilise.
###end p 45
###begin p 46
###xml 150 154 146 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Spiecker1">[10]</xref>
###xml 156 160 152 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Node1">[19]</xref>
###xml 435 438 412 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-BishopBailey1">[1]</xref>
###xml 440 443 417 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Marx1">[2]</xref>
8,9-EET, and 11,12-EET, but not 14,15-EET activated PPARalpha. 11,12-EET in contrast to 14-15-EET is highly anti-inflammatory and vascular protective [10], [19]. Therefore, we propose that PPARalpha is a likely anti-inflammatory target for 11,12-EET and CYP2J2. Indeed we found the combination of PPARalpha and CYP2J2 abolished IL-1beta induced NFkappaB activation; a central pro-inflammatory transcription factor and PPARalpha target [1], [2].
###end p 46
###begin p 47
###xml 80 83 80 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Zeldin1">[9]</xref>
###xml 85 89 85 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Node1">[19]</xref>
###xml 340 343 336 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Cowart1">[5]</xref>
###xml 344 347 340 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Liu1">[7]</xref>
###xml 678 681 670 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Zeldin1">[9]</xref>
###xml 791 794 783 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Cowart1">[5]</xref>
###xml 796 799 788 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Liu1">[7]</xref>
###xml 801 804 793 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Liu2">[8]</xref>
Many EETs, including 14,15-EET, can also act as cellular hyperpolarising agents [9], [19], however, since 14,15-EET was inactive in our system, hyperpolarization mechanisms are highly unlikely to be involved. Our results are consistent with previous findings that EETs and some of their metabolites can directly bind and activate PPARalpha [5]-[7]. Although 14,15-EET did not activate PPARalpha in our hands, its CYP4A hydroxylase 14,15-EET metabolite 20,14,15-HEET, was the post potent EET product we tested. EETs can be rapidly metabolised by at least 10 different intracellular pathways, and it is estimated that when given exogenously <10% is available free within the cell [9]. Our results therefore do indicate that alternative CYP2J2 products exist or further unknown EET metabolites [5], [7], [8] are potential endogenous PPARalpha activators.
###end p 47
###begin p 48
###xml 207 211 207 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Nelson1">[20]</xref>
###xml 527 531 527 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Athirakul1">[17]</xref>
###xml 57 60 <span type="species:ncbi:9606">man</span>
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
###xml 93 98 <span type="species:ncbi:9606">human</span>
###xml 115 120 <span type="species:ncbi:10090">mouse</span>
###xml 345 350 <span type="species:ncbi:10090">mouse</span>
###xml 455 460 <span type="species:ncbi:10090">mouse</span>
###xml 521 526 <span type="species:ncbi:10090">mouse</span>
###xml 768 773 <span type="species:ncbi:10090">mouse</span>
There is considerable species difference between CYPs in man and in the mouse. CYP2J2 is the human isoform, in the mouse the situation is far more complex with up to 8 putative homologues (CYP2J5 - CYP2J13; [20]). Since epoxygenases are ubiquitous and potentially have many roles, examining the role of endogenous epoxygenases especially in the mouse is extremely difficult. We therefore chose as our main model the established cardiac specific CYP2J2-Tr mouse. We did however test the recently described CYP2J5 knockout mouse [17], the only CYP2J knockout available. However, we did not detect a change in the fasting response or in PDK4 expression, suggesting a lack of involvement of CYP2J5 in PPARalpha ligand generation or the more likely compensation from other mouse CYP2J or CYP2C EET-producing epoxygenases that are present.
###end p 48
###begin p 49
###xml 544 548 532 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Djouadi1">[21]</xref>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
###xml 305 310 <span type="species:ncbi:10090">mouse</span>
###xml 371 375 <span type="species:ncbi:10090">mice</span>
###xml 501 505 <span type="species:ncbi:10090">mice</span>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
The selective augmentation of PDK4 in cardiac-specific CYP2J2-Tr mice occurred only in female mice. The fasting PPARalpha response was much stronger in males, and we believe maximally activated. Interestingly, our results are consistent with known gender differences in cardiac PPARalpha responses in the mouse. Pharmacological stress of the hearts of PPARalpha knockout mice with Etomoxir to prevent mitochondrial fatty acid import, results in cardiac lipid accumulation and a 100% mortality of male mice but only 25% mortality of female mice [21].
###end p 49
###begin p 50
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n vitro</italic>
###xml 79 85 75 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n vivo</italic>
###xml 266 273 258 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 520 528 504 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 533 540 517 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 228 233 <span type="species:ncbi:10090">mouse</span>
In conclusion, in vitro CYP2J2 activates PPARalpha without exogenous stimuli. In vivo CYP2J2 does not appear to be rate-limiting as PPARalpha target gene (PDK4) expression is only augmented in cardiac-specific CYP2J2 transgenic mouse upon fasting. Therefore, CYP2J2 in vivo is an enzyme apparently quiescent, but capable or responding to changes in lipid availability to generate endogenous PPARalpha agonists and thereby integrate transcriptional fasting events. CYP2J2 products activate PPARs, in particular PPARalpha in vitro and in vivo. As lipid-metabolising CYP enzymes have a widespread expression, utilise a variety of lipid substrates and produce a large family of oxidised biologically active lipid mediators, we suggest that lipid metabolising CYPs may represent an important source of PPAR ligands throughout the body.
###end p 50
###begin p 51
###xml 290 294 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Spiecker2">[22]</xref>
###xml 296 300 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Lee1">[23]</xref>
PPARalpha is known as a controller of lipid metabolism and inflammation. Linking CYP2J2 and epoxygenases to PPARalpha has many potential clinical implications. Variants of CYP2J2 with lower activity are known in some populations to be linked to an increased risk of coronary artery disease [22], [23]. Epoxygenases such as CYP2J2 in addition to metabolising arachidonic acid may also regulate xenobiotic drug metabolism. Understanding how epoxygenases are regulated, the mediators they produce, and where they work, will give us novel information on biomarkers for dyslipidaemia and inflammation, allow us to understand side-effects of drugs metabolised by epoxygenases, and help us to design novel PPARalpha ligands based on the structure of high affinity EETs and their metabolites.
###end p 51
###begin title 52
Materials and Methods
###end title 52
###begin title 53
Materials
###end title 53
###begin p 54
###xml 536 540 520 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Wu2">[24]</xref>
###xml 550 554 534 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Sugden2">[25]</xref>
###xml 506 512 <span type="species:ncbi:9986">Rabbit</span>
HEK293 cells were from ATCC. pEGFPN-1 and pNFkB-luc were from Clontech. pGL-2 was from Promega (Southampton, UK). pCMXmPPARalpha, pACOg.Luc, and h6/29 hPPARalpha were gifts from Dr Ruth Roberts (AstraZeneca; Maccelsfield, U.K.), pCMX-mPPARdelta was from Dr Ronald Evans (Salk Institute, La Jolla, USA), pDR-1 was from Dr Bert Vogelstein (Johns Hopkins University, Baltimore, USA), pCMX-mPPARgamma was from Dr Christopher Glass (UCSD, San Diego, USA). Novafector was from VennNova (Pompano Beach, FL, USA). Rabbit polyclonal anti-CYP2J2 [24] and PDK2 [25] were raised as previously described. Anti-PDK4 antibodies were generously provided by Professor Bob Harris (Indianapolis, USA). CYP2J2 metabolites were from Cayman Chemical Company (Axxora, Nottingham, UK). SKF525A was from Biomol (Affiniti Research Products, Exeter, UK). Plasma insulin ELISA was from Mercodia (Uppsala, Sweden). Plasma glucose kits were from Roche Diagnostics (Lewes, East Sussex, UK). WAKO kits for plasma triacylglycerol were from Alpha Labs. (Eastleigh, Hants, UK). ECL reagents, hyperfilm were from Amersham Biosciences (Little Chalfont, Buckinghamshire, UK). Bradford reagents for protein estimation were purchased from BioRad Ltd. (Hemel Hempstead, Hertfordshire. UK). All other reagents were from Sigma (Poole, Dorset, UK).
###end p 54
###begin title 55
Cell culture and transfections
###end title 55
###begin p 56
###xml 119 120 113 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 239 243 233 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-BishopBailey2">[26]</xref>
###xml 278 282 272 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Swales1">[27]</xref>
###xml 613 617 607 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-1">[28]</xref>
###xml 541 546 <span type="species:ncbi:10090">mouse</span>
HEK293 were maintained in DMEM containing, supplemented with Antibiotic/Antimycotic mix, and 10% FCS; 37degreesC; 5% CO2; 95% air. Cells were transfected with Novafector and Luciferase assays performed, essentially as previously described [26] but modified for a 96 well format [27]. Luciferase activity was normalised to cell protein (BCA assay). Global cellular changes, cell morphology, and GFP expression were recorded on a Nikon TE2000 inverted florescent microscope, with a SPOT RT digital camera. In some experiments organ culture of mouse cardiac tissue was performed, essentially as previously described [28].
###end p 56
###begin title 57
Ethics Statement
###end title 57
###begin p 58
All animal studies were approved by the National Institute of Environmental Health Sciences Animal Care and Use Committee.
###end p 58
###begin title 59
Animal experiments
###end title 59
###begin p 60
###xml 111 115 107 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Seubert1">[15]</xref>
###xml 148 152 144 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Swales1">[27]</xref>
###xml 24 39 <span type="species:ncbi:10090">transgenic mice</span>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
Cardiac-specific CYP2J2 transgenic mice (alpha-MHC promoter driven) and littermate wild type C57BL6/J controls [15] along with CYP2J5 knockout mice [27] have been described previously. Animals were allowed food and water ad libitum or fasted for 24 h. In some experiments mice were given SKF525A (30 mg/kg; i.p) or vehicle (sterile PBS) immediately prior to initiation of the 24 h fasting/non-fasting period.
###end p 60
###begin title 61
Immunoblotting and assays
###end title 61
###begin p 62
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Sugden1">[13]</xref>
###xml 93 97 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Wu2">[24]</xref>
###xml 99 103 99 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007421-Sugden2">[25]</xref>
###xml 287 292 <span type="species:ncbi:10090">mouse</span>
###xml 369 372 <span type="species:ncbi:10116">rat</span>
PDK1, -2, -4 and E1a and CYP2J2 protein levels were determined as previously described [13], [24], [25]. For animal experiments each representative immunoblot presented are results from a single gel exposed for a uniform duration, and each lane represents a preparation from a different mouse. Plasma immunoreactive insulin concentrations were measured by ELISA, using rat insulin as a standard. Plasma glucose concentrations were determined by a glucose oxidase method. Plasma NEFA and TAG levels were determined spectrophotometrically using commercial kits.
###end p 62
###begin title 63
Supporting Information
###end title 63
###begin p 64
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 126 130 <span type="species:ncbi:10090">mice</span>
###xml 254 258 <span type="species:ncbi:10090">mice</span>
###xml 505 509 <span type="species:ncbi:10090">mice</span>
Blood glucose and PDK4 expression in female fed and fasted wild type and CYP2J5 knockout (-/-) mice. Wild type and CYP2J5 -/- mice have similar basal levels of plasma glucose. Following 24 h of fasting, blood glucose dropped in both wild type and CYP2J2 mice to equivalent levels, while the PPARalpha target gene PDK4 was induced to similar levels in the heart, liver and kidney. The non-PPARalpha target genes E1a and PDK2 (data not shown), were unaffected by fasting. Similar results were found in male mice. This data represents the mean+/-s.e.m. for n = 4 animals per group. * denotes p<0.05 by paired t-test between fed and fasted levels.
###end p 64
###begin p 65
(0.03 MB DOC)
###end p 65
###begin p 66
Click here for additional data file.
###end p 66
###begin title 67
References
###end title 67
###begin article-title 68
Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation.
###end article-title 68
###begin article-title 69
Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.
###end article-title 69
###begin article-title 70
Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner.
###end article-title 70
###begin article-title 71
Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase.
###end article-title 71
###begin article-title 72
The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands.
###end article-title 72
###begin article-title 73
14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator activated receptor-alpha.
###end article-title 73
###begin article-title 74
The antiinflammatory effect of laminar flow: The role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase.
###end article-title 74
###begin article-title 75
Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells.
###end article-title 75
###begin article-title 76
Epoxygenase pathways of arachidonic acid metabolism.
###end article-title 76
###begin article-title 77
Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids.
###end article-title 77
###begin article-title 78
PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.
###end article-title 78
###begin article-title 79
Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha).
###end article-title 79
###begin article-title 80
Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs.
###end article-title 80
###begin article-title 81
Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor alpha.
###end article-title 81
###begin article-title 82
Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway.
###end article-title 82
###begin article-title 83
PPAR signaling in the control of cardiac energy metabolism.
###end article-title 83
###begin article-title 84
###xml 28 32 <span type="species:ncbi:10090">mice</span>
Increased blood pressure in mice lacking cytochrome P450 2J5.
###end article-title 84
###begin article-title 85
Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase.
###end article-title 85
###begin article-title 86
Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.
###end article-title 86
###begin article-title 87
###xml 51 56 <span type="species:ncbi:10090">mouse</span>
###xml 61 66 <span type="species:ncbi:9606">human</span>
Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, p.seudogenes and alternative-splice variants.
###end article-title 87
###begin article-title 88
###xml 132 136 <span type="species:ncbi:10090">mice</span>
A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice.
###end article-title 88
###begin article-title 89
Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease.
###end article-title 89
###begin article-title 90
CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study.
###end article-title 90
###begin article-title 91
###xml 46 51 <span type="species:ncbi:9606">human</span>
Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart.
###end article-title 91
###begin article-title 92
Role of peroxisome proliferator-activated receptor-alpha in the mechanism underlying changes in renal pyruvate dehydrogenase kinase isoform 4 protein expression in starvation and after refeeding.
###end article-title 92
###begin article-title 93
###xml 113 119 109 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12, 14</sup>
###xml 135 136 131 132 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2.
###end article-title 93
###begin article-title 94
The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression.
###end article-title 94
###begin article-title 95
Price S, Evans TW, Mitchell JA. Nitric oxide supports atrial function in sepsis: relevance to side effects of inhibitors in shock.
###end article-title 95
###begin p 96
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 96
###begin p 97
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was partly funded by grants from the British Heart Foundation (FS/04/047; FS/04/075; BS/02/002; PG/08/070/25464), Diabetes UK, the William Harvey Research Foundation, the Wellcome Trust, the European Community FP6 funding (LSHM-CT-2004-0050333), and the Intramural Research Programs of the National Institutes of Health, NIEHS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 97

